Ribas, Antoni; Wolchok, Jedd D (2018) Cancer immunotherapy using checkpoint blockade. Science 359:1350-1355
|
Park, Jung Wook; Lee, John K; Sheu, Katherine M et al. (2018) Reprogramming normal human epithelial tissues to a common, lethal neuroendocrine cancer lineage. Science 362:91-95
|
Hong, Aayoung; Moriceau, Gatien; Sun, Lu et al. (2018) Exploiting Drug Addiction Mechanisms to Select against MAPKi-Resistant Melanoma. Cancer Discov 8:74-93
|
Nowicki, Theodore S; Hu-Lieskovan, Siwen; Ribas, Antoni (2018) Mechanisms of Resistance to PD-1 and PD-L1 Blockade. Cancer J 24:47-53
|
Puig-Saus, Cristina; Parisi, Giulia; Garcia-Diaz, Angel et al. (2018) IND-Enabling Studies for a Clinical Trial to Genetically Program a Persistent Cancer-Targeted Immune System. Clin Cancer Res :
|
Moschos, Stergios J; Sullivan, Ryan J; Hwu, Wen-Jen et al. (2018) Development of MK-8353, an orally administered ERK1/2 inhibitor, in patients with advanced solid tumors. JCI Insight 3:
|
Tsoi, Jennifer; Robert, Lidia; Paraiso, Kim et al. (2018) Multi-stage Differentiation Defines Melanoma Subtypes with Differential Vulnerability to Drug-Induced Iron-Dependent Oxidative Stress. Cancer Cell 33:890-904.e5
|
Grasso, Catherine S; Giannakis, Marios; Wells, Daniel K et al. (2018) Genetic Mechanisms of Immune Evasion in Colorectal Cancer. Cancer Discov 8:730-749
|
Lee, John K; Bangayan, Nathanael J; Chai, Timothy et al. (2018) Systemic surfaceome profiling identifies target antigens for immune-based therapy in subtypes of advanced prostate cancer. Proc Natl Acad Sci U S A 115:E4473-E4482
|
Eroglu, Zeynep; Zaretsky, Jesse M; Hu-Lieskovan, Siwen et al. (2018) High response rate to PD-1 blockade in desmoplastic melanomas. Nature 553:347-350
|
Showing the most recent 10 out of 72 publications